📣 We are excited to join the #oncology community at #ASCO24! #OranoMed and its partner Radiomedix, Inc. are thrilled and honored to announce that results from our Phase 2 study with ²¹²Pb-DOTAMTATE (AlphaMedix™) have been accepted for oral presentation at the ASCO Annual Meeting in Chicago. Join us to discover our latest advancements presented by Prof. Jonathan Strosberg (Moffitt Cancer Center, Tampa/FL) during the rapid oral abstract session on Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary. 📅 Monday, June 3rd, 2024 | 10:57 AM CT “Safety, tolerability and efficacy of ²¹²Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.” Abstract: #4020 (https://lnkd.in/etwMJhDZ) We are very much looking forward to sharing these results, that also contributed to the recent FDA Breakthrough Therapy designation. #ASCO2024 #Oncology #AlphaTherapy #MedicalInnovation #CancerResearch #Radiopharmaceuticals #FutureOfMedicine
Excited for the presentation!
Innovative VP of Sales & Marketing | Experienced in Business Intelligence & Data Engineering | Driving Success with Data-Driven Sales & Marketing Strategies
5moThat's fantastic news, and congratulations to OranoMed and Radiomedix, Inc.! It's incredible to see the advancements in oncology being presented at ASCO24. The acceptance of results from the Phase 2 study with 212Pb-DOTAMTATE is a significant achievement and speaks volumes about the potential impact of AlphaMedix™ in treating unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors. I'll be sure to keep an eye out for updates on your presentation. Best of luck at ASCO, and here's to continued progress in cancer research and medical innovation! #ASCO2024 #Oncology #AlphaTherapy #MedicalInnovation #CancerResearch #Radiopharmaceuticals #FutureOfMedicine